S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Where Are The Markets Going Next? (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Gas prices increase in NJ, around nation amid higher demand
Where Are The Markets Going Next? (Ad)pixel
Lanterns and crescents: more retailers court Ramadan buyers
Shipbuilder Austal executives accused of inflating earnings
Where Are The Markets Going Next? (Ad)pixel
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Where Are The Markets Going Next? (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Gas prices increase in NJ, around nation amid higher demand
Where Are The Markets Going Next? (Ad)pixel
Lanterns and crescents: more retailers court Ramadan buyers
Shipbuilder Austal executives accused of inflating earnings
Where Are The Markets Going Next? (Ad)pixel
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Where Are The Markets Going Next? (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Gas prices increase in NJ, around nation amid higher demand
Where Are The Markets Going Next? (Ad)pixel
Lanterns and crescents: more retailers court Ramadan buyers
Shipbuilder Austal executives accused of inflating earnings
Where Are The Markets Going Next? (Ad)pixel
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Where Are The Markets Going Next? (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Gas prices increase in NJ, around nation amid higher demand
Where Are The Markets Going Next? (Ad)pixel
Lanterns and crescents: more retailers court Ramadan buyers
Shipbuilder Austal executives accused of inflating earnings
Where Are The Markets Going Next? (Ad)pixel
No more room for vroom? Paris votes on banishing e-scooters
NASDAQ:MGEN

Miragen Therapeutics - MGEN Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$25.21
▼
$26.01
50-Day Range
$14.34
▼
$23.01
52-Week Range
$4.66
▼
$34.05
Volume
763,115 shs
Average Volume
134,027 shs
Market Capitalization
$99.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

MGEN stock logo

About Miragen Therapeutics (NASDAQ:MGEN) Stock

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.

Receive MGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Miragen Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MGEN Stock News Headlines

January 19, 2021 | finance.yahoo.com
miRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appointments, Including Expansion of Leadership Team
December 17, 2020 | finance.yahoo.com
miRagen Enters into License Agreement with Xencor for use of Xtend™ Antibody Technology for Investigational Antibodies to Treat Thyroid Eye Disease
April 2, 2023 | Vantage Point (Ad)
What To Do With Your Trades Today
There’s a tool that scans and picks the best stocks… and could give you all the consistency you need in your trading… No matter what happens in the market. Revealed Here: A.I. Predicted Stock Forecasts pixel
November 10, 2020 | seekingalpha.com
Miragen Therapeutics EPS beats by $0.03
November 10, 2020 | finance.yahoo.com
miRagen Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
November 9, 2020 | finance.yahoo.com
Iovance (IOVA) Q3 Earnings Beat Estimates, Pipeline in Focus
November 1, 2020 | bloomberg.com
Miragen Therapeutics Inc
October 30, 2020 | seekingalpha.com
MiRagen Therapeutics shares skyrocket 156% on Viridian acquisition, inks PIPE deal for $91M
April 2, 2023 | Legacy Research (Affiliate) (Ad)
Bear market expert makes new prediction
Nobody believed Larry Benedict's prediction in February 2020. The DOW plunged 3.5%, and he told CNBC, "It seems like there's much more to come." Within a month, the market plummeted 34%. Then, nobody believed Larry at the start of last year, either. He predicted that "all the indexes will be negative for the year," with the Nasdaq leading the way. Once again, he was spot-on.
October 29, 2020 | finance.yahoo.com
Looking Into Miragen Therapeutics's Return On Capital Employed
October 28, 2020 | benzinga.com
Looking Into Miragen Therapeutics's Return On Capital Employed
October 28, 2020 | benzinga.com
Why Miragen's Stock Is Trading Higher Today
October 28, 2020 | seekingalpha.com
MiRagen Therapeutics (MGEN) shares skyrocket 156% on Viridian acquisition, inks PIPE deal for $91M
October 28, 2020 | finance.yahoo.com
miRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc.
October 17, 2020 | finance.yahoo.com
miRagen Announces Internal Review of Preliminary Topline Data for the Phase 2 SOLAR Clinical Trial of Cobomarsen in Patients with Cutaneous T-Cell Lymphoma (CTCL)
October 6, 2020 | benzinga.com
Mid-Day Market Update: Crude Oil Rises Over 3%; Miragen Therapeutics Shares Slide
October 5, 2020 | seekingalpha.com
MiRagen's cobomarsen short of the mark in mid-stage blood cancer study
September 14, 2020 | seekingalpha.com
miRagen names new CEO; to review portfolio
September 14, 2020 | finance.yahoo.com
miRagen Announces Leadership Transition and Review of Strategic Alternatives
August 24, 2020 | finance.yahoo.com
How Should Investors React To Miragen Therapeutics' (NASDAQ:MGEN) CEO Pay?
August 24, 2020 | finance.yahoo.com
How Should Investors React To Miragen Therapeutics' (NASDAQ:MGEN) CEO Pay?
August 20, 2020 | finance.yahoo.com
miRagen Announces Results of Meeting With FDA Regarding the Design of Pivotal Trial for Cobomarsen in ATLL
August 5, 2020 | seekingalpha.com
miRagen Therapeutics' (MGEN) CEO Bill Marshall on Q2 2020 Results - Earnings Call Transcript
August 5, 2020 | finance.yahoo.com
Signal Genetics, Inc. (MGEN) Reports Q2 Loss, Misses Revenue Estimates
August 5, 2020 | seekingalpha.com
Miragen Therapeutics EPS beats by $0.05, misses on revenue
August 5, 2020 | finance.yahoo.com
miRagen Reports Second Quarter 2020 Financial Results and Provides Business Updates
August 4, 2020 | finance.yahoo.com
miRagen to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
See More Headlines
Receive MGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Miragen Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MGEN Company Calendar

Last Earnings
11/10/2020
Today
4/01/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Medical Laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MGEN
CUSIP
N/A
CIK
1590750
Web
www.signalgenetics.com
Phone
720-643-5200
Fax
N/A
Employees
45
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($20.09)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-41,870,000.00
Net Margins
-1,393.50%
Pretax Margin
N/A
Return on Equity
-141.66%
Return on Assets
-88.74%

Debt

Debt-to-Equity Ratio
0.20
Current Ratio
4.23
Quick Ratio
4.23

Sales & Book Value

Annual Sales
$4.46 million
Price / Sales
22.29
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.78 per share
Price / Book
3.75

Miscellaneous

Outstanding Shares
3,908,000
Free Float
N/A
Market Cap
$99.42 million
Optionable
Not Optionable
Beta
1.66

Key Executives

  • Mr. Jason A. Leverone CPA (Age 46)
    CPA, CFO, Sec. & Treasurer
    Comp: $355k
  • Dr. William Stuart Marshall Ph.D. (Age 56)
    Co-Founder & Sr. Technical Advisor
    Comp: $521k
  • Dr. Diana Escolar (Age 58)
    Chief Medical Officer
    Comp: $484.38k
  • Ms. Lee M. Rauch (Age 65)
    CEO & Director
  • Dr. Jonathan Violin Ph.D. (Age 45)
    Pres & COO
  • Eric N. Olson
    Co-Founder & Chairman of Scientific Advisory Board
  • Dr. Michael R. Bristow (Age 75)
    Co-Founder & Member of the Scientific Advisory Board
  • Dr. Marvin H. Caruthers (Age 80)
    Co-Founder & Scientific Advisory Board Member
  • Mr. Vahe Bedian Ph.D.
    Chief Scientific Officer
  • Dr. Aimee L. Jackson
    VP of Research

Key Competitors

View All Competitors













MGEN Stock - Frequently Asked Questions

How were Miragen Therapeutics' earnings last quarter?

Miragen Therapeutics, Inc. (NASDAQ:MGEN) announced its earnings results on Tuesday, November, 10th. The medical research company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.03. Miragen Therapeutics had a negative net margin of 1,393.50% and a negative trailing twelve-month return on equity of 141.66%.

What other stocks do shareholders of Miragen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Miragen Therapeutics investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), KushCo (KSHB), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Pennsylvania Real Estate Investment Trust (PEI), Organigram (OGI), Novan (NOVN) and Aeterna Zentaris (AEZS).

What is Miragen Therapeutics' stock symbol?

Miragen Therapeutics trades on the NASDAQ under the ticker symbol "MGEN."

What is Miragen Therapeutics' stock price today?

One share of MGEN stock can currently be purchased for approximately $25.44.

How much money does Miragen Therapeutics make?

Miragen Therapeutics (NASDAQ:MGEN) has a market capitalization of $99.42 million and generates $4.46 million in revenue each year. The medical research company earns $-41,870,000.00 in net income (profit) each year or ($20.09) on an earnings per share basis.

How can I contact Miragen Therapeutics?

Miragen Therapeutics' mailing address is 6200 LOOKOUT ROAD, BOULDER CO, 80301. The official website for the company is www.signalgenetics.com. The medical research company can be reached via phone at 720-643-5200 or via email at daniel@lifesciadvisors.com.

This page (NASDAQ:MGEN) was last updated on 4/2/2023 by MarketBeat.com Staff